BioWorld - Tuesday, January 27, 2026

BioWorld Science

Aug. 16, 2021

View Archived Issues

Polymer-mediated "immunocloaking" - A new paradigm for combating transplant rejection?

Read More

Phase I trial begins for DVX-201 allogeneic NK cells in COVID-19 patients

Read More

Trial starts enrollment to assess LY-3361237 in patients with psoriasis

Read More

TYK2 inhibitor NDI-034858 enters phase II investigation for plaque psoriasis

Read More

MedImmune patents new ADCs for cancer

Read More

Kangpu Biopharmaceuticals divulges CRBN-binding isoindolines

Read More

Beijing Jacobio Pharmaceuticals presents new AURK1 inhibitors

Read More

Apeximmune Therapeutics describes anti-B7-H4 constructs for cancer

Read More

Primary endpoint not met in phase II trial of trimodulin in patients with severe COVID-19

Read More

Lomecel-B improves physical function in phase IIb study in patients with aging frailty

Read More

Phase I study of tyrosine kinase 2 inhibitor ICP-332 begins in China

Read More

Phase Ib data reported for ITPP in patients with hepatopancreatobiliary tumors

Read More

SPTBN1 genetic variants found to be associated with neurodevelopmental syndrome

Read More

Leptin linked to severity of COVID-19

Read More

Enanta's HBV treatment begins phase I study

Read More

LAVA Therapeutics cleared to initiate clinical trial of LAVA-1207

Read More

FDA lifts clinical hold on trial of Danon disease treatment RP-A501

Read More